Trials / Conditions / Pneumonia, Pneumococcal

Pneumonia, Pneumococcal

29 registered clinical trials studyying Pneumonia, Pneumococcal.

Status	Trial	Sponsor	Phase
Completed	Study of Gamma PN3 in the Elderly NCT06562790	GPN Vaccines	Phase 1
Completed	Pneumonia Vaccine Education Intervention Study NCT06136832	Geisinger Clinic	N/A
Completed	Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure NCT05799976	Mitesh Patel	N/A
Completed	A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly With NCT05526716	Merck Sharp & Dohme LLC	Phase 3
Completed	A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-experienced A NCT05420961	Merck Sharp & Dohme LLC	Phase 3
Completed	A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infant NCT05412030	GlaxoSmithKline	Phase 2
Unknown	Paediatric Pneumococcal Pneumonia in Malaysia Prior to and During Pneumococcal Conjugate Vaccine (PCV) Impleme NCT04923035	IMU University, Malaysia	—
Unknown	Evaluation of Immunogenicity and Safety of Combined Immunization of COVAX (Produced in Wuhan) and PPV23 / IIV4 NCT05079152	China National Biotec Group Company Limited	Phase 4
Completed	Evaluation of Immunogenicity and Safety of Combined Immunization of COVID-19 Vaccine (Produced in Beijing) and NCT04790851	China National Biotec Group Company Limited	Phase 4
Completed	Prevention of Missed Opportunities for HIV Diagnosis by Promoting HIV Testing of Patients With Pneumococcal Pn NCT04909268	Centre Hospitalier Universitaire de Nice	—
Completed	Evaluation of Safety and Immunogenicity of Combined Immunization of PPV23 and IIV4 NCT04559204	China National Biotec Group Company Limited	Phase 4
Unknown	Immunogenicity and Safety Study of 15-Valent Pneumococcal Conjugate Vaccine in 2-month-old and 3-month-old Hea NCT04357522	Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd	Phase 3
Completed	A Phase 1/Phase 2 Study of Polyvalent Pneumococcal Conjugate Vaccine (V116) in Adults (V116-001) NCT04168190	Merck Sharp & Dohme LLC	Phase 1 / Phase 2
Completed	Study of 10-valent Pneumococcal Conjugate Vaccine (Pneumosil) Administered in a 2+1 Schedule to Healthy Infant NCT03896477	PATH	Phase 3
Completed	Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020) NCT03950856	Merck Sharp & Dohme LLC	Phase 3
Unknown	Safety Study of 15-Valent Pneumococcal Conjugate Vaccine in Healthy Volunteers Aged Above 2 Months NCT04108845	Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd	Phase 1
Completed	An Epidemiological Survey to Establish the Spectrum of Circulating Serotypes of S. Pneumoniae, in Patients Old NCT04464291	The Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy (IACMAC)	N/A
Completed	Quantitative Polymerase Chain Reaction for Improved Detection of Pneumococci in CAP "CAPTAIN" NCT03315403	Medical Center Alkmaar	—
Terminated	Myocardial Injury and Severe Pneumococcal Pneumonia NCT03058211	Alejandro Rodriguez Oviedo , MD	—
Completed	Immunogenicity and Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Healthy Volunteers Aged 2 Years NCT04278248	Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd	Phase 3
Completed	Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants NCT03197376	PATH	Phase 3
Completed	Evaluation of PCV Schedules in a Naive Population in Vietnam NCT02961231	Nagasaki University	Phase 4
Completed	Safety, Tolerability, and Efficacy Study of Prophylactic S. Pneumoniae Vaccine Following Challenge With S. Pne NCT02116998	Genocea Biosciences, Inc.	Phase 2
Completed	Dose-Finding Study of S.Pneumoniae Whole Cell Vaccine Adsorbed to Alum (PATH-wSP) in Healthy Kenyan Adults and NCT02097472	PATH	Phase 1 / Phase 2
Completed	Epidemiologic Study Of The Distribution Of Vaccine-Type Streptococcus Pneumoniae Serotypes In Adults In The US NCT01086397	Pfizer	—
Completed	Study Evaluating the Effiacy of a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in Adults NCT00744263	Pfizer	Phase 4
Completed	Dynamics of the Immune Response in Children to the 23-valent Pneumococcal Capsular Polysaccharide Vaccine (Pne NCT03460730	KEMRI-Wellcome Trust Collaborative Research Program	Phase 1
Terminated	Ceftriaxone Vs Levofloxacin on Cytokine Expression in Pneumococcal Pneumonia NCT00429975	Hospital Mutua de Terrassa	Phase 4
Completed	New Antibiotic to Treat Patients With Community-acquired Pneumonia Due to a Specific Bacteria (S. Pneumoniae P NCT00035269	Pfizer	Phase 3